VentureMed Group is a commercial stage medical device company developing innovative and minimally invasive devices for the treatment of peripheral artery disease (PAD) FLEX, the Company’s lead technology platform, is an innovative, cost-effective device for the endovascular treatment of patients suffering from PAD and arterio-venous access complications
Fund VentureMed’s strategic clinical plan (which includes current and future trials in the US and Europe) and key operational and research and development programs Support regulatory and reimbursement initiatives for the Company’s lead technology platform, FLEX Expand the company’s worldwide commercial team
If you would like to learn more information about this transaction contact us below.